Screening and Prevention of Extra Colonic Cancer in Hereditary Non-polyposis Colorectal Cancer

  • R. Mittal
  • T. H. A. Arulampalam
Part of the GI Surgery Annual book series (GISA, volume 22)


Hereditary non-polyposis colorectal cancer (HNPCC), also known as Lynch syndrome, is the most common form of hereditary colon cancer, accounting for about 2–5 % of all colorectal cancers [1]. It was first described by Dr Henry Lynch in 1966, when he noticed a high incidence of colorectal, stomach and endometrial cancer in two extended families [2].


Gastric Cancer Endometrial Cancer Lynch Syndrome National Comprehensive Cancer Network Oral Contraceptive Pill 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003;348:919–32.CrossRefPubMedGoogle Scholar
  2. 2.
    Lynch HT, Shaw MW, Magnuson CW, Larsen AL, Krush AJ. Hereditary factors in cancer. Study of two large midwestern kindreds. Arch Intern Med 1966;117:206–12.CrossRefPubMedGoogle Scholar
  3. 3.
    Barrow E, Alduaij W, Robinson L, Shenton A, Clancy T, Lalloo F, et al. Colorectal cancer in HNPCC: Cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. Clin Genet 2008;74:233–42.CrossRefPubMedGoogle Scholar
  4. 4.
    Hampel H, Stephens JA, Pukkala E, Sankila R, Aaltonen LA, Mecklin JP, et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: Later age of onset. Gastroenterology 2005;129:415–21.CrossRefPubMedGoogle Scholar
  5. 5.
    Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000;342:69–77.CrossRefPubMedGoogle Scholar
  6. 6.
    Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999;116:1453–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261–8.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Watson P, Vasen HF, Mecklin JP, Bernstein I, Aarnio M, Järvinen HJ, et al. The risk of extracolonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008;123:444–9.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Koessler T, Oestergaard MZ, Song H, Tyrer J, Perkins B, Dunning AM, et al. Common variants in mismatch repair genes and risk of colorectal cancer. Gut 2008;57:1097–101.CrossRefPubMedGoogle Scholar
  10. 10.
    Lu KH, Dinh M, Kohlmann W, Watson P, Green J, Syngal S, et al. Gynecologic cancer as a ‘sentinel cancer’ for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 2005;105:569–74.CrossRefPubMedGoogle Scholar
  11. 11.
    Meyer LA, Broaddus RR, Lu KH. Endometrial cancer and Lynch syndrome: Clinical and pathologic considerations. Cancer Control 2009;16:14–22.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Bonadona V, Bonaïti B, Olschwang S, Grandjouan S, Huiart L, Longy M, et al.; French Cancer Genetics Network. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011;305:2304–10.CrossRefPubMedGoogle Scholar
  13. 13.
    Obermair A, Youlden DR, Young JP, Lindor NM, Baron JA, Newcomb P, et al. Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma. Int J Cancer 2010;127:2678–84.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997;6:105–10.CrossRefPubMedGoogle Scholar
  15. 15.
    Hendriks YM, Wagner A, Morreau H, Menko F, Stormorken A, Quehenberger F, et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: Impact on counseling and surveillance. Gastroenterology 2004;127:17–25.CrossRefPubMedGoogle Scholar
  16. 16.
    Kempers MJ, Kuiper RP, Ockeloen CW, Chappuis PO, Hutter P, Rahner N, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: A cohort study. Lancet Oncol 2011;12:49–55.CrossRefPubMedGoogle Scholar
  17. 17.
    Broaddus RR, Lynch HT, Chen LM, Daniels MS, Conrad P, Munsell MF, et al. Pathologic features of endometrial carcinoma associated with HNPCC: A comparison with sporadic endometrial carcinoma. Cancer 2006;106:87–94.CrossRefPubMedGoogle Scholar
  18. 18.
    Westin SN, Lacour RA, Urbauer DL, Luthra R, Bodurka DC, Lu KH, et al. Carcinoma of the lower uterine segment: A newly described association with Lynch syndrome. J Clin Oncol 2008;26:5965–71.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Dijkhuizen FP, Mol BW, Brölmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: A meta-analysis. Cancer 2000;89:1765–72.CrossRefPubMedGoogle Scholar
  20. 20.
    Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: A systematic review. JAMA 2006;296:1507–17.CrossRefPubMedGoogle Scholar
  21. 21.
    Renkonen-Sinisalo L, Bützow R, Leminen A, Lehtovirta P, Mecklin JP, Järvinen HJ. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer 2007;120:821–4.CrossRefPubMedGoogle Scholar
  22. 22.
    Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006;354:261–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Chen LM, Yang KY, Little SE, Cheung MK, Caughey AB. Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families. Obstet Gynecol 2007;110:18–25.CrossRefPubMedGoogle Scholar
  24. 24.
    Celentano V, Luglio G, Antonelli G, Tarquini R, Bucci L. Prophylactic surgery in Lynch syndrome. Tech Coloproctol 2011;15:129–34.CrossRefPubMedGoogle Scholar
  25. 25.
    Pistorius S, Kruger S, Hohl R, Plaschke J, Distler W, Saeger HD, et al. Occult endometrial cancer and decision making for prophylactic hysterectomy in hereditary nonpolyposis colorectal cancer patients. Gynecol Oncol 2006;102:189–94.CrossRefPubMedGoogle Scholar
  26. 26.
    Weiss NS, Sayvetz TA. Incidence of endometrial cancer in relation to the use of oral contraceptives. N Engl J Med 1980;302:551–4.CrossRefPubMedGoogle Scholar
  27. 27.
    Lu KH, Loose DS, Yates MS, Nogueras-Gonzalez GM, Munsell MF, Chen LM, et al. Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depoprovera for prevention of endometrial cancer in women with Lynch syndrome. Cancer Prev Res (Phila) 2013;6:774–81.CrossRefGoogle Scholar
  28. 28.
    Egoavil C, Alenda C, Castillejo A, Paya A, Peiro G, Sánchez-Heras AB, et al. Prevalence of Lynch syndrome among patients with newly diagnosed endometrial cancers. PLoS One 2013;8:e79737.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Wang Y, Wang Y, Li J, Cragun J, Hatch K, Chambers SK, et al. Lynch syndrome related endometrial cancer: Clinical significance beyond the endometrium. J Hematol Oncol 2013;6:22.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Barrow E, Robinson L, Alduaij W, Shenton A, Clancy T, Lalloo F, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: A report of 121 families with proven mutations. Clin Genet 2009;75:141–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Watson P, Bützow R, Lynch HT, Mecklin JP, Järvinen HJ, Vasen HF, et al.; International Collaborative Group on HNPCC. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2001;82:223–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Capelle LG, Van Grieken NC, Lingsma HF, Steyerberg EW, Klokman WJ, Bruno MJ, et al. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology 2010;138:487–92.CrossRefPubMedGoogle Scholar
  33. 33.
    Renkonen-Sinisalo L, Sipponen P, Aarnio M, Julkunen R, Aaltonen LA, Sarna S, et al. No support for endoscopic surveillance for gastric cancer in hereditary non-polyposis colorectal cancer. Scand J Gastroenterol 2002;37:574–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, et al.; Mallorca group. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): Recommendations by a group of European experts. Gut 2013;62:812–23.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW; American College of Gastroenterology. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 2015;110:223–62; quiz 263.Google Scholar
  36. 36.
    Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, et al. Guidelines on genetic evaluation and management of Lynch syndrome: A consensus statement by the US Multisociety Task Force on colorectal cancer. Am J Gastroenterol 2014;109:1159–79.CrossRefPubMedGoogle Scholar
  37. 37.
    Engel C, Loeffler M, Steinke V, Rahner N, Holinski-Feder E, Dietmaier W, et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol 2012;30:4409–15.CrossRefPubMedGoogle Scholar
  38. 38.
    Schulmann K, Brasch FE, Kunstmann E, Engel C, Pagenstecher C, Vogelsang H, et al.; German HNPCC Consortium. HNPCC-associated small bowel cancer: clinical and molecular characteristics. Gastroenterology 2005;128:590–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Saurin JC, Pilleul F, Soussan EB, Manière T, D’Halluin PN, Gaudric M, et al.; Capsule Commission of the French Society of Digestive Endoscopy (SFED). Small-bowel capsule endoscopy diagnoses early and advanced neoplasms in asymptomatic patients with Lynch syndrome. Endoscopy 2010;42:1057–62.CrossRefPubMedGoogle Scholar
  40. 40.
    Van der Post RS, Kiemeney LA, Ligtenberg MJ, Witjes JA, Hulsbergen-van de Kaa CA, Bodmer D, et al. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet 2010;47:464–70.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Marsh GM, Cassidy LD. The Drake Health Registry Study: Findings from fifteen years of continuous bladder cancer screening. Am J Ind Med 2003;43:142–8.CrossRefPubMedGoogle Scholar
  42. 42.
    Myrhøj T, Andersen MB, Bernstein I. Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer. Fam Cancer 2008;7:303–7.CrossRefPubMedGoogle Scholar
  43. 43.
    Win AK, Young JP, Lindor NM, Tucker KM, Ahnen DJ, Young GP, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: A prospective cohort study. J Clin Oncol 2012;30:958–64.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Barrow PJ, Ingham S, O’Hara C, Green K, McIntyre I, Lalloo F, et al. The spectrum of urological malignancy in Lynch syndrome. Fam Cancer 2013;12:57–63.CrossRefPubMedGoogle Scholar
  45. 45.
    Grindedal EM, Møller P, Eeles R, Stormorken AT, Bowitz-Lothe IM, Landrø SM, et al. Germline mutations in mismatch repair genes associated with prostate cancer. Cancer Epidemiol Biomarkers Prev 2009;18:2460–7.CrossRefPubMedGoogle Scholar
  46. 46.
    Kastrinos F, Mukherjee B, Tayob N, Wang F, Sparr J, Raymond VM, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA 2009;302:1790–5.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, et al.; International Cancer of Pancreas Screening (CAPS) Consortium. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013;62:339–47. Erratum in: Gut 2014;63:178. Hamell, Pascal [corrected to Hammell, Pascal]. Gut 2014;63:1978. Hammell, Pascal [corrected to Hammel, Pascal].Google Scholar
  48. 48.
    Vasen HF, Morreau H, Nortier JW. Is breast cancer part of the tumor spectrum of hereditary nonpolyposis colorectal cancer? Am J Hum Genet 2001;68:1533–5.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© T.K. Chattopadhyay 2015

Authors and Affiliations

  • R. Mittal
    • 1
  • T. H. A. Arulampalam
    • 1
  1. 1.ICENI Centre, Colchester HospitalColchesterUK

Personalised recommendations